The Omnipod 5 is the first and only tubeless hybrid closed loop insulin pump available in the United States. It pairs a 3-day disposable adhesive pod (containing the insulin reservoir, motor, and cannula) with a smartphone app or handheld controller, and uses the SmartAdjust algorithm with Dexcom G6, Dexcom G7, or Abbott Libre 2 Plus continuous glucose monitor data to automatically adjust insulin delivery every 5 minutes. FDA approved for type 1 diabetes (age 2 and up) and type 2 diabetes (adults), with insurance access often through pharmacy benefit.
How the Omnipod 5 Works
- Insulin is loaded into the pod, which is then activated by the controller or app
- The pod adheres to skin via integrated adhesive; the cannula deploys automatically
- The pod communicates wirelessly with the controller or paired smartphone
- Glucose data from a connected CGM streams to the pod every 5 minutes
- The SmartAdjust algorithm raises, lowers, or pauses basal insulin based on glucose trend and target
- Users manually bolus for meals using the SmartBolus calculator
- The pod is replaced every 72 hours (3 days)
Components and Specifications
| Component | Specification |
|---|---|
| Pod size | 1.6 by 2.1 by 0.5 inches |
| Pod weight | 26 grams (filled) |
| Reservoir capacity | 200 units (minimum fill 85 units) |
| Wear duration | 72 hours (3 days) |
| Cannula | Integrated automatic insertion, soft Teflon |
| Waterproof rating | IPX8 — 8 feet for 60 minutes |
| Compatible insulin | Humalog, Novolog, Admelog |
| Compatible CGM | Dexcom G6, Dexcom G7, FreeStyle Libre 2 Plus |
| Controller | Insulet PDM or compatible smartphone (iPhone, select Android) |
| Algorithm | SmartAdjust (target adjustable 110 to 150 mg/dL by time of day) |
SmartAdjust Algorithm
The SmartAdjust algorithm is the heart of the Omnipod 5:
- Reads glucose values from paired CGM every 5 minutes
- Compares current value and trend to user-set target (110, 120, 130, 140, or 150 mg/dL)
- Increases insulin delivery when glucose is above target and rising
- Reduces or suspends insulin when glucose is below target or falling
- Adapts over time based on the user’s actual basal needs (total daily insulin)
- Continues operating in “limited mode” with last-known patterns if CGM signal is lost
- SmartBolus calculator separately handles meal and correction doses
Indications and Approved Use
- Type 1 diabetes — age 2 and older (FDA approved 2022)
- Type 2 diabetes — adults age 18 and older (FDA approved 2024)
- Total daily insulin — minimum 5 units, maximum 75 units in any 8-hour window
- Body weight — minimum 10 kg (22 lb) for pediatric use
Clinical Evidence — CLOUD-101 Trial
The CLOUD-101 pivotal trial (Garg et al., 2022) studied 240 patients with type 1 diabetes using Omnipod 5 for 3 months:
- Time in Range (70 to 180 mg/dL) improved from 64.5 percent to 73.9 percent in adults
- Pediatric Time in Range improved from 52.5 percent to 68.0 percent
- A1C dropped 0.4 to 0.7 percentage points
- Time below 70 mg/dL decreased
- No severe hypoglycemia or diabetic ketoacidosis attributed to system function
Subsequent real-world data confirmed durable benefit at 12 months.
Comparison with Other AID Systems
| Feature | Omnipod 5 | Tandem Control-IQ | Medtronic 780G |
|---|---|---|---|
| Tubing | None (tubeless) | Tubed | Tubed |
| Pump body location | On skin | Clipped (or on skin for Mobi) | Clipped to clothing |
| Reservoir | 200 units | 300 units (t:slim X2), 200 units (Mobi) | 300 units |
| Site change | 3 days (whole pod) | 3 days (set), reservoir 3 days | 3 days (set), reservoir 3 days, Extended Set 7 days |
| Compatible CGM | Dexcom G6, G7, Libre 2 Plus | Dexcom G6, G7 | Guardian 4 |
| Algorithm target | 110-150 mg/dL adjustable | 112.5 mg/dL fixed | 100, 110, or 120 mg/dL |
| Auto-corrections | Through basal modulation | Yes, conservative | Yes, every 5 min (most aggressive) |
| Pediatric age | 2 and up | 6 and up | 7 and up |
| Type 2 approval | Yes (adults) | No formal AID approval | No formal AID approval |
Benefits
- Tubeless — no tubing to catch or disconnect; full mobility
- Waterproof — swim, shower, exercise without removing
- Phone control option — bolus and adjust settings from smartphone
- Approved for type 2 diabetes — only AID system with this indication
- Pharmacy benefit access — easier insurance authorization at many plans
- Adjustable target — set different targets for day, night, or exercise
- Three CGM options — most flexibility of any AID system
- Auto-cannula insertion — no manual needle insertion
Drawbacks and Considerations
- Minimum 85-unit fill — wasteful for very low-dose pediatric users
- 200-unit max — high-dose users may exhaust pod before 3 days
- Adhesive issues — some users react or have pods that fall off in heat or sweat
- Visible patch — body image and clothing considerations
- Pod wastes insulin — small amount left in pod at change is discarded
- No tubing means full pod replacement on failure — entire 200 units lost if pod errors
- Cost — without insurance, $900 to $1,200 per month
Site Care
- Rotate sites among abdomen, upper outer arm, upper outer thigh, upper buttock, and lower back
- Move at least 1 inch from previous site
- Apply barrier wipe (Skin-Tac, Mastisol) for better adhesion if needed
- Use overlay tape (KT Tape, Tegaderm) for extra adhesion during sweaty activities
- Inspect site daily for redness or leaking
- If pod alarms or fails, remove and apply a new pod immediately
Side Effects and Risks
- Diabetic ketoacidosis — risk if pod fails and is not replaced; pumps deliver only rapid-acting insulin
- Hypoglycemia — reduced vs MDI but still possible; algorithm suspends insulin as glucose falls
- Skin reactions — adhesive irritation, contact dermatitis
- Lipohypertrophy — minimized by site rotation
- Cannula kinks or occlusions — sudden hyperglycemia; replace pod
- Pod adhesive failure — premature detachment
- CGM signal loss — system reverts to limited mode; manual basal adjustments may be needed
Cost and Insurance
| Item | Typical Cost (US) |
|---|---|
| Starter kit (PDM controller) | $0 to $800 (often covered) |
| Pods (10-count box, 30-day supply) | $900 to $1,200 retail; $50 to $300 typical insurance copay |
| Insulin (Humalog, Novolog) | $25 to $100 monthly copay |
| CGM (Dexcom G7, Libre 2 Plus) | $50 to $200 monthly copay |
| Annual total with insurance | $1,200 to $5,000 typical |
Related Reading
For pump fundamentals see how does an insulin pump work. Compare with other AID systems in our Medtronic 780G and Tandem Mobi guides, or read the broader hybrid closed loop systems overview. For broader context see insulin therapy and all treatment options.
External Resources
The FDA medical device database contains Omnipod 5 approval documentation, and the American Diabetes Association Standards of Care 2024 covers AID systems and pump prescribing.
The Bottom Line
The Omnipod 5 is the first and only tubeless hybrid closed loop insulin pump in the United States. It pairs a 3-day disposable adhesive pod with the SmartAdjust algorithm and uses continuous glucose monitor data from Dexcom G6, Dexcom G7, or Abbott Libre 2 Plus to automatically adjust insulin every 5 minutes. FDA approved for type 1 diabetes (age 2 and older) and type 2 diabetes (adults) — making it the broadest-indication AID system available. Strengths include waterproof tubeless design, phone control, adjustable glucose targets, and pharmacy benefit access at many insurers. Drawbacks include the 85-unit minimum pod fill, 200-unit maximum, and adhesive issues some users experience. Clinical trials and real-world data show meaningful improvement in Time in Range and A1C with low hypoglycemia. Talk to your endocrinologist and diabetes educator about whether Omnipod 5 fits your needs, insurance coverage, and willingness to wear a visible patch.
